PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.

Bibliographic Details
Main Authors:	O. Mompel, C. Amorós, P. López-Menargues, C. Játiva, A. Cámara, R. García-Serra, M. J. Lis, M. T. Orero, S. Ortiz, M. Linares
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851168.63343.97

Similar Items

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
by: C. Amorós, et al.
Published: (2022-06-01)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
by: Giulia Bega, et al.
Published: (2021-12-01)

Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin’s Lymphoma or Mantle-Cell Lymphoma
by: Brenda Cristie Edina, et al.
Published: (2022-04-01)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
by: Rocío García-Serra, et al.
Published: (2023-08-01)

2084
by: Jane Otado, et al.
Published: (2017-09-01)

Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab
by: Thomas Crowhurst, et al.
Published: (2020-12-01)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
by: Yuki Shimizu, et al.
Published: (2023-06-01)

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine
by: Nydia Panitz, et al.
Published: (2021-08-01)

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review
by: Sih-Han Liao, et al.
Published: (2017-05-01)

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
by: Gloria Margiotta-Casaluci, et al.
Published: (2023-03-01)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
by: M. Corrochano, et al.
Published: (2022-06-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy
by: Yang Yin-long, et al.
Published: (2011-12-01)

Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab
by: Akie Hirata, et al.
Published: (2022-12-01)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
by: Tatsuro Jo, et al.
Published: (2014-07-01)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
by: Koh Ki-Ryang, et al.
Published: (2009-08-01)

Perforating folliculitis secondary to bendamustine-rituximab chemotherapy: A case report
by: Rowan Monteiro, et al.
Published: (2017-01-01)

Painful, plantar nodules in cutaneous macroglobulinosis: Successful treatment with rituximab and bendamustine
by: Carmine D'Acunto, PhD, et al.
Published: (2020-10-01)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
by: Friederike Braulke, et al.
Published: (2022-12-01)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
by: Vincenzo Maria Perriello, et al.
Published: (2023-05-01)

Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient
by: Gabriele Magliano, et al.
Published: (2021-08-01)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
by: K. Lisenko, et al.
Published: (2017-05-01)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
by: W. Jurczak, et al.
Published: (2022-06-01)

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS
by: J.-M. Sancho, et al.
Published: (2022-06-01)

Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review
by: Rungjirajittranon T, et al.
Published: (2021-10-01)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
by: J. P. Sharman, et al.
Published: (2022-06-01)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
by: Kohei Kamegai, et al.
Published: (2022-08-01)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
by: Georg Hess, et al.
Published: (2020-06-01)

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
by: M. Novo, et al.
Published: (2022-06-01)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
by: I. Zamanillo, et al.
Published: (2022-06-01)

PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES
by: Mitsuhito Hirano, et al.
Published: (2023-08-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients
by: Anna Vanni, et al.
Published: (2023-12-01)

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
by: Sara Galimberti, et al.
Published: (2017-06-01)

Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol)
by: E. S. Nesterova, et al.
Published: (2018-10-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
by: Myrna Candelaria, et al.
Published: (2021-01-01)

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
by: M. S. Dal, et al.
Published: (2022-06-01)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
by: Won Sriwijitalai, et al.
Published: (2019-02-01)